Loading
Low-Dose Oliceridine Group / Obesity / High-Dose Oliceridine Group · Phase 4 Trial
ClinicalTrials.gov · August 12, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a Phase 4 dose-finding trial registration for a planned but not-yet-recruiting study of combined oliceridine and propofol sedation in obese patients undergoing gastroscopy. No results are available; the registry record describes the rationale, design, and planned primary outcome (ED50 and ED95 of propofol combined with oliceridine at 3 minutes post-insertion) but provides no efficacy or safety data.
Phase 4, Interventional, Randomized, Parallel, Triple masking, Treatment purpose. Obesity, Gastrointestinal Endoscopy; age from 18 Years; to 65 Years. Intervention: Low-Dose Oliceridine Group; High-Dose Oliceridine Group. n = 80.
This is a Phase 4 dose-finding trial registration for a planned but not-yet-recruiting study of combined oliceridine and propofol sedation in obese patients undergoing gastroscopy. No results are available; the registry record describes the rationale, design, and planned primary outcome (ED50 and ED95 of propofol combined with oliceridine at 3 minutes post-insertion) but provides no efficacy or safety data.
Safety outcomes and adverse events are not specified in the primary outcome measures reported here.
This trial is designed to inform sedation protocols for a high-risk population (obese patients) and may help establish safer dosing of a newer opioid agent (oliceridine) in combination with propofol. However, results are not yet available and should not be anticipated from this registry record.
This is a Phase 4 trial registration with no results posted; it describes a planned dose-finding study in a specific population that has not yet begun recruiting.
As stated by the source record.
Quoted from the source exactly as published.
This trial is designed to inform sedation protocols for a high-risk population (obese patients) and may help establish safer dosing of a newer opioid agent (oliceridine) in combination with propofol. However, results are not yet available and should not be anticipated from this registry record.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07759778). This is a study registration, not published results. Lead sponsor: Lu Yi. Recruitment status: NOT_YET_RECRUITING. Phase: PHASE4. Study type: INTERVENTIONAL. Enrollment: 80 participants (ESTIMATED). Conditions: Obesity, Gastrointestinal Endoscopy. Interventions: DRUG: Low-Dose Oliceridine Group; DRUG: High-Dose Oliceridine Group. Primary outcome measures: Effective Dose (ED50 and ED95) of Propofol Combined with Oliceridine for Gastroscope Insertion , Within 3 minutes after gastroscope insertion. Brief summary: The purpose of this study is to find the right dose of two medications, oliceridine and propofol, when used together for sedation in patients with obesity undergoing a painless gastroscope procedure. Currently, standard sedation methods using other opioids can sometimes cause breathing problems, especially in patients with obesity. Oliceridine is a newer medication that may provide good pain relief with a lower risk of these side effects. However, the best dose of propofol when combined with oliceridine for this specific patient group is not yet clear. This study will enroll patients with obesity (BMI ≥ 28 kg/m²) who are scheduled for a routine painless gastroscopy. Participants will receive the study medications during their procedure, and the medical team will carefully monitor their vital signs and sedation level. The study aims to find the most effective and safe dose combination to help guide future clinical practice.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.